Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Uptrend seems to have held. Nice looking hammer now.

Now up 7.58%

MMs behaved exactly as I thought they would!

Nice one Jumpin

Big Al-Hammer? Where did the carpenter come from?very strange this BPRG;-)

thanks for equis link,very good

JC, m8. Looking after all the "average-downers".

LOL!

Don't need a book in charting, just watch for the "bend at the end of the trend". See one?

If we have to get technical, there is always the uptrend in RSI in chart above not to mention higher low (or 1-2-3) at 60p. Not entirely surprising as 60p was a pig to breakthrough going north.

Off to kiss the Blarney Stone now. Hope I don't fall off.

Saw it the other week Bones. ;-))

Still not an uptrend, but stands a decent chance of getting one underway. Still think 75/80p gonna be tricky, though. She'll be on a flyer when/if it happens.

Bones-we've got shooting stars,hammers,black holes,do we really need the Blarney Stone as well?LOL

emailpat - LOL!

Rather disappointed to see a lack of anything today. Price dropped, no volume, etc. In fact lowest volume in 3 months!!

PRM might have made people realise what can happen if news does go against you.

Ne'er mind - next week's another week (funnily enough), so we'll see what happens, but definitely getting the impression the fizz is going, be it "up-fizz" or "down-fizz". Typical closed period?

BioProgress appoints JPMorgan for US Nasdaq listing
http://www.uk-wire.com/cgi-bin/articles/200408040700155964b.html

Brokers note finally out. Interesting that they say "as broker to the company we make no recomendation and leave investors to draw their own conclusions as to the value of the company. Thought they might have said stonking buy !

Janus, sounds like CS do not know how to value the company then!!

Janus, thats probably they are going to be replaced with alarger and more commited broker, who will put the interests of BPRG and its shareholders first.

CS are a bunch of crooks

Year to December 2003A 2004E 2005E 2006E
Turnover (m) 0.9 5.4 14.4 32.8
Pre-tax profit (m) (1.7) 1.5 5.9 13.1
EPS (p) (3.4) 1.3 4.1 8.0
P/E (x) n/a 46.1 14.6 7.5
Cash (m) 1.8 12.0 14.1

I especially like this bit:

In summary this is a disruptive technology in one of the worlds largest
industries. Given the strong Intellectual Property that exists on the
technology, operating margins should be very strong and profitability in
2006/07 enough to drive forward the valuation. Our estimates for 2006
should be viewed as conservative, with the companys own internal targets
being 3x our estimated level of profitability.

BioProgress investors have had a real roller coaster of a ride since our feature back in October 2003 at 55p; the shares progressed to an all time high of 158p in February, since then the shares have steadily re-traced back to a low point of 60p on July 7.

Todays 14% thrust north to 71p can be attributed JPMorgan appointment, and of course, the long awaited Collins Stewart broker note; the first of its kind since the company floated on the AIM market just over a year ago. BioProgress announced that JPMorgan Chase Bank has been appointed as the US depositary for BioProgress listing of its Ordinary Shares in the form of American Depositary Receipts (ADRs) on the NASDAQ National Market in the USA, JPMorgan should help drum up US support for BPRG.

BioProgress looks have a three pronged turbine thrust developing behind it; There can be little doubt that such a high profile blue chip appointment in JPMorgan should increased buy pressure once London listed shares are transferred to the US as ADRs. Observers have suggested to me that 20p up side can be expected per million shares transferred as ADRs. I must confess to a head ache once I digested the complexity of the example when explained to me.no I am not going to try! Moving swiftly on.


BioProgress investors have had a real roller coaster of a ride since our feature back in October 2003 at 55p; the shares progressed to an all time high of 158p in February, since then the shares have steadily re-traced back to a low point of 60p on July 7.

Todays 14% thrust north to 71p can be attributed JPMorgan appointment, and of course, the long awaited Collins Stewart broker note; the first of its kind since the company floated on the AIM market just over a year ago. BioProgress announced that JPMorgan Chase Bank has been appointed as the US depositary for BioProgress listing of its Ordinary Shares in the form of American Depositary Receipts (ADRs) on the NASDAQ National Market in the USA, JPMorgan should help drum up US support for BPRG.

BioProgress looks have a three pronged turbine thrust developing behind it; There can be little doubt that such a high profile blue chip appointment in JPMorgan should increased buy pressure once London listed shares are transferred to the US as ADRs. Observers have suggested to me that 20p up side can be expected per million shares transferred as ADRs. I must confess to a head ache once I digested the complexity of the example when explained to me.no I am not going to try! Moving swiftly on.


BioProgress investors have had a real roller coaster of a ride since our feature back in October 2003 at 55p; the shares progressed to an all time high of 158p in February, since then the shares have steadily re-traced back to a low point of 60p on July 7.

Todays 14% thrust north to 71p can be attributed JPMorgan appointment, and of course, the long awaited Collins Stewart broker note; the first of its kind since the company floated on the AIM market just over a year ago. BioProgress announced that JPMorgan Chase Bank has been appointed as the US depositary for BioProgress listing of its Ordinary Shares in the form of American Depositary Receipts (ADRs) on the NASDAQ National Market in the USA, JPMorgan should help drum up US support for BPRG.

BioProgress looks have a three pronged turbine thrust developing behind it; There can be little doubt that such a high profile blue chip appointment in JPMorgan should increased buy pressure once London listed shares are transferred to the US as ADRs. Observers have suggested to me that 20p up side can be expected per million shares transferred as ADRs. I must confess to a head ache once I digested the complexity of the example when explained to me.no I am not going to try! Moving swiftly on.

here's the full article.........

Elric Lloyd-Langton

August 4 2004


BioProgress investors have had a real roller coaster of a ride since our feature back in October 2003 at 55p; the shares progressed to an all time high of 158p in February, since then the shares have steadily re-traced back to a low point of 60p on July 7.

Todays 14% thrust north to 71p can be attributed JPMorgan appointment, and of course, the long awaited Collins Stewart broker note; the first of its kind since the company floated on the AIM market just over a year ago. BioProgress announced that JPMorgan Chase Bank has been appointed as the US depositary for BioProgress listing of its Ordinary Shares in the form of American Depositary Receipts (ADRs) on the NASDAQ National Market in the USA, JPMorgan should help drum up US support for BPRG.

BioProgress looks have a three pronged turbine thrust developing behind it; There can be little doubt that such a high profile blue chip appointment in JPMorgan should increased buy pressure once London listed shares are transferred to the US as ADRs. Observers have suggested to me that 20p up side can be expected per million shares transferred as ADRs. I must confess to a head ache once I digested the complexity of the example when explained to me.no I am not going to try! Moving swiftly on.

The second thrust could continue to develop now that the ever imminent CS note has finally materialised, and now circling the BBs. The interesting thing about BioProgress, is that a mere c8% of the companys ordinary shares are held by institutions, leaving the remainder with Company employees and of course, the volatile trading minds of private investors, who I must confess to being part of. The point I am making is this; now that the CS broker note is out, one must assume (if you like) that institutions will now feel less constrained, thus take a closer look at the company, previously restricted without any official research document to fall back on, no one to blame syndrome, of course institutions do have a rigid investment criteria to which some must stick to; a broker note, or lack of, may just impair ones judgment a little.

The third thrust should come from the closure of the bear positions as they clamber for the exit before margin call a comes knocking, after all, they have fed long enough, helped by the lengthy due diligence periods similar to Wyeth`s, who have an option to use XGEL SWALLOW technology. These are complex times, as well as time consuming; FMC Corporation for example in addition to its own internal patent department employed no less than five firms of patent attorneys to scrutinise the BioProgress patent portfolio. This rigorous due diligence which would have also been performed by Perrigo and FMC Corporation is supportive to the companys case.

The bears have been feeding on the back of investor pessimism due to the lack of understanding the nature of the complex nature surrounding due diligence periods. Should Wyeth be convinced of BioProgress technology, we should here more by mid September, by which time, the bears who have braved todays signals will surely clamber for the exit and become buyers.

With the likelihood of the SEO debacle being heard after the judge returns from his jollies, further impetus may be evident, assuming the BioProgress patent case is a good one. Nevertheless, the potential downside is minimal, given the companys view that the out come will not impact on its existing patent portfolio.

There can be no doubting that the shares will be driven by news items in the future, as this is often the case; a case in point is the continued negotiations relating to licensing two other BioProgress dosage forms, namely SEPTUM and WAFERTAB.

The TABWRAP technology competes with gelatin, cellulose spray coating
and sugar tablet coating technologies in the 900bn per year solid tablet global market. BioProgress is working with a number of other pharmaceutical companies on projects involving the transfer of branded OTC products into the TABWRAP technology.

BioProgress is known to be in discussions with at least two other major pharmaceutical companies on projects to transfer existing coated tablet products into the TABWRAP technology.

Although CS seemed unable to put a price target on BioProgress, CS did say, Our estimates for 2006 should be viewed as conservative, with the companys own internal targets being 3x our estimated level of profitability. CS also pointed out that the recent placing underpinned the shares potential, and further suggested that the company would not need further funding to achieve profitability.

The company is intending to operate on the Tetrapak model of selling machines that can only use its proprietary film. (the very point Edward made in his initial story) As such profitability in later years could be very significant, although in the early period the numbers will be modest.

I think the bears were long gone 2-3 weeks back!

Keep up will you?

;-))